← All organizations
Highest phase reached
Phase 4
First clinical trial
Jul 1, 2021Last known activity
Nov 30, 2024
Timeline
2020s
- Jul 1, 2021
Hellenic Institute for the Study of Sepsis— Founded
Drugs by trial phase (14 distinct, 20 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (4 own, 0 via acquisition)
Phase 2 (9 own, 0 via acquisition)
Indications
Studied for
- Communicable Diseases
- Coronary Disease
- Coronavirus Infections
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Emergencies
- Gram-Negative Bacterial Infections
- Heart Diseases
- Hidradenitis
- Hidradenitis Suppurativa
- Immune System Diseases
- Infections
- Lung Diseases, Obstructive
- Macrophage Activation Syndrome
- Multiple Organ Failure
- Pulmonary Disease, Chronic Obstructive
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Respiratory Insufficiency
- Respiratory Tract Infections
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Sepsis
- Severe Acute Respiratory Syndrome
- Toxemia
- Virus Diseases
Recent trials (25)
- NCT06694701Lead sponsorPhase 2Nov 30, 2024
- NCT06294600Lead sponsorPhase 3Feb 12, 2024
- NCT05926505Lead sponsorPhase 2/Phase 3Sep 6, 2023
- NCT05926505Study chairPhase 2/Phase 3Sep 6, 2023
- NCT05785442Lead sponsorPhase 2Mar 6, 2023
- NCT05785442Study chairPhase 2Mar 6, 2023
- NCT05304715Lead sponsorPhase 2Apr 13, 2022
- NCT05277285Lead sponsorPhase 2Apr 1, 2022
- NCT04990232Lead sponsorPhase 2Jul 29, 2021
- NCT04990232Study chairPhase 2Jul 29, 2021
- NCT04724044Lead sponsorPhase 3Jan 25, 2021
- NCT04680949Lead sponsorPhase 3Dec 23, 2020
- NCT04680949Study chairPhase 3Dec 23, 2020
- NCT04414267Lead sponsorPhase 4May 26, 2020
- NCT04398004Lead sponsorPhase 2May 6, 2020
Details
- Founded
- Athens, GR Jul 1, 2021
- Last known activity
- Nov 30, 2024